Immune Ageing and Viral Co-Factors

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Immune-Based Interventions for HIV Infection and AIDS Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University Medical.
Evaluation of Human Thymic Function during Health and HIV-1 Infection
HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the.
Immuno-virological discordance in treated suppressed patients Julià Blanco IGTP/IrsiCaixa Badalona, Catalonia, Spain.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Immunosenescence - Results of BELFRAIL (and INCIVAR) By Adriaensen Wim Department of Public Health and Primary Care, KU Leuven & UCL, Belgium.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Toronto I-II 4:00 pm The end of AIDS: HIV as a chronic inflammatory disease Steven Deeks Professor of medicine in residence at the University of California,
Concepts in Basic Science and Translational Research
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.
HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
Peter W. Hunt, MD Associate Professor of Medicine in Residence
British Columbia Centre for Excellence in HIV/AIDS Julio Montaner MD, FRCPC, FCCP, FRSC Director, BC-Centre for Excellence on HIV/AIDS, Providence Health.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
Clinic-based Translational Research Cohort/ Clinical Trial Immunology Core Lab (Sinclair) Basic Immunology Lab (McCune) Virology Core Lab (Liegler) Basic.
David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.
Isolated Hepatitis B Core Antibody
Slide 1 of 44 From SG Weibel, MD, at San Francisco, CA: May 6, 2016, IAS-USA. Getting Hotter As We Get Older Sara Gianella Weibel, MD Assistant Professor.
Diego Ripamonti - Malattie Infettive - Bergamo Simposio HOT TOPICS Hot topics in HIV 2015.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division.
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
HIV-infected patients, and have proliferative defects
HIV and Aging: A Paradigm Shift in the Management of HIV Disease
State of HIV Cure Research
The role of unknown risk factors in coronary heart disease
Inflammation Markers and The Risk of Non-AIDS Events
HIV and Inflammation Jihad Slim, MD June 2016.
HIV Cure: Current Status and Future Perspectives
Confounding factors and choice of controls in studies of immune activation and inflammation Caroline Sabin.
Clinic-based Translational Research
The Aging Liver in the Aging HIV and HCV Patients
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Hepatitis C virus in the human liver transplantation model
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Clinic-based Translational Research
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Residual Disease and Immune Activation/Inflammation on ART
Successful and Maladaptive T Cell Aging
Volume 141, Issue 4, Pages e3 (October 2011)
When to START During an OI
<?xml version="1.0"?><AllQuestions />
Steven Yukl UCSF and San Francisco VA
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Presentation transcript:

Immune Ageing and Viral Co-Factors Peter W. Hunt, MD Associate Professor of Medicine Division of Experimental Medicine, UCSF

Disclosures Consultant Merck Gilead Viiv

Potential Role of Inflammation in Driving Morbidity in Older HIV+ Individuals ART Toxicity Age- associated Morbidity Lifestyle Persistent Inflammation CMV HCV Deeks and Phillips, BMJ, 2009

CMV

10% of circulating memory T cell repertoire is CMV-specific! CMV elicits massive immune responses even in asymptomatic HIV- individuals 10% of circulating memory T cell repertoire is CMV-specific! Sylwester/Picker, JEM, 2005

CD8+ T Cell Proliferation & Maturation with CMV ↑Telomere Length CD57+, ↓Telomere Length “Senescence” phenotype associated with mortality in elderly Wikby, Exp Ger, 2002 Hadrup, JI, 2006 Antigen Lee, PLoS One, 2014 CD28- Memory CD8+ Cells CD28+CD27+ CCR7+RA- CD27+CCR7-RA- CD27-CCR7-RA- CD27-CCR7-RA+ Central Memory Transitional Effector Memory TEMRA

CMV does not impair (and may enhance) flu vaccine responses in young HIV- individuals Old CMV IgG- CMV IgG+ Furman/Davis, Science Transl Med, 2015

CMV Causes CD8 Expansion and Inflammation in HIV Infection CD8+ T Cell Counts IP-10 sTNF-RII D-Dimer CMV causes ↑CX3CR1 expression, trafficking of T cells/monos to vascular tissue CX3CR1+ CD8s also express PAR-1, which can activate coagulation cascade CMV viremia (or prior end organ dz) predicts venous thromboembolism in HIV Freeman, JID, 2014 (see also: Sacre, AIDS, 2011; Mudd, JID, 2016; Musselwhite, AIDS 2011)

in HIV+ Patients with CD4<350 despite ART Blocking Asymptomatic CMV Replication with Valganciclovir ↓ Immune Activation in HIV+ Patients with CD4<350 despite ART -4.4% HIV- Median Valacyclovir, which has strong anti-HSV1/2 but minimal anti-CMV activity, failed to decrease immune activation (Yi et al, CID, 2013). Hunt et al, JID, 2011

Cardiovascular Effects of CMV

Higher CMV-specific CD8 IFN-g Production Associated with More Atherosclerosis Hsue et al, AIDS, 2006 (see also: Parrinello, JID, 2012; Lo, AIDS, 2010)

CMV Sero-status Predicts Non-AIDS Events (and less so AIDS…): ICONA Cohort Strongest effect for CAD (HR 2.3) CMV replicates in vascular endothelium and appears to contribute to transplant vasculopathy (Valantine, Circ, 1999) Lichtner et al, JID, 2015 (see also Hsue, AIDS, 2006)

A role of CMV in other aspects of HIV pathogenesis?

CMV may plausibly drive clonal proliferation of HIV-infected cells Seminal CMV Shedding Associated with Higher PBMC HIV Reservoirs during ART CMV may plausibly drive clonal proliferation of HIV-infected cells Gianella, JV, 2014

CMV May Also Contribute to Microbial Translocation in HIV Infection Maidji, PLoS Path, 2017

Hepatitis C Virus

No increased risk of CAD or cancer HCV appeared to increase the risk of: T2DM Kidney disease Osteoporotic fractures Only T2DM risk declined with Rx (IFN-based) (see also editorial by Lo Re III, CID, 2017)

Comparable reductions in sCD163 (P≤0.0004 for both) Greater and More Rapid Reversal of Type I IFN Signaling with DAA vs IFN-based HCV Rx IFN-based SVR Baseline Week 4 Week 12 P=0.004 -19% -47% DAA-based SVR Baseline Week 4 Week 12 P<0.001 -73% -70% Comparable reductions in sCD163 (P≤0.0004 for both) Good: DAAs reduce biomarkers that predict morbidity Bad: DAAs may result in loss of HBV control Mascia, PLoS One, 2017 (also: Tenorio, JID, 2014; Knudsen, JID, 2016; Chen, Hepatology, 2017)

Early Increase in LDL Cholesterol during DAA Treatment of HCV Oxidized LDL also increases during DAA Tx (Biliotti, CROI 2017, #575) Restoration of health or increased CAD risk? IFNs may suppress LDL (Schectman, Arterio Thromb 1992) Townsend, ARHR, 2016 (see also Frias, CROI 2017, #573)

Reactive Hyperemia Index Inconsistent Effects of DAA-based HCV Tx on CAD Surrogate Markers in Treated HIV (n=20) Reactive Hyperemia Index by peripheral arterial tonometry D-dimer Level (ng/ml) Baseline Post-SVR Better Worse Baseline Post-SVR …but sICAM-1, sE-selectin, and sCD163 all declined (P<0.01) Chew, Int. Co-Morbidities Workshop, 2016

Summary CMV appears to increase immune activation in treated HIV and may plausibly contribute to: Cardiovascular, thromboembolic disease HIV reservoirs and microbial translocation Need an interventional study to assess these hypotheses HCV treatment with DAAs causes massive reversal of Type I interferons Impact on CAD surrogate markers is mixed Impact on extra-hepatic events still unclear

Acknowledgements Hunt and McCune Labs Core Immunology Lab UCSD Elizabeth Sinclair, Lorrie Epling Jeff Milush, Chris Baker SFGH Cardiology Priscilla Hsue UARTO Helen Byakwaga David Bangsberg Mark Siedner NIAID/VRC Jason Brenchley Danny Douek University of Sao Paulo Vivian Avelino-Silva Esper Kallas CWRU Michael Lederman Mike Freeman Hunt and McCune Labs Rachel Rutishauser Josh Vasquez Charline Bacchus-Souffan Louise Swainson Ma Somsouk Sulggi Lee Ivan Vujkovich-Cvijin Mike McCune SCOPE/OPTIONS/UCSF Steve Deeks Jeff Martin Hiroyu Hatano Rick Hecht Chris Pilcher Rebecca Hoh SCOPE and OPTIONS Teams UCSF Drug Studies Unit Yong Huang UCSD Sara Gianella Davey Smith UCLA Kara Chew R01AI110271, R56AI100765, 1R21AI087035, 1R21AI07877 DDCF CSDA Roche, Inc.